Autopsy report · NCT02696291
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
Cause of deathFunding or business
“Product development halted for business reasons.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 9 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Emergent BioSolutions
- Sponsor type
- Industry
- Conditions
- Viral Infection
- Interventions
- UV-4B 30 mg oral solution; UV-4B 75 mg oral solution; UV-4B 150 mg oral solution; UV-4B X mg (dose to be determined) oral solution; UV-4B Y mg (dose to be determined) oral solution; Placebo
- Participants
- 7
- Sites
- 2
- Countries
- United States
Trials that died the same way
- A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
“The development was stopped due to company's strategy consideration” - Clinical Evaluation of Systane® Balance in Dry Eye Subjects
“Discontinuation of product development” - The Study for Evaluate of Satety and Dfficacy of Hemostatic Device
“The company stopped manufacturing the product” - Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers
“Product development project closed prematurely” - A Study to Test if TEV-53275 is Effective in Relieving Asthma
“Stopped for strategic reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.